|
Home | Medical-Newswire.Com:
|
(EMAILWIRE.COM, August 28, 2008 ) HAMPTON, VA -- HST Global, Inc. (OTCBB: HSTC) is pleased to announce that it has, through its contracted partner EBITDA Capital LLC of Newport Beach California and its group of associates, commenced negotiations with the Chinese Government for both direct investment and a license for their treatment protocols.
Mr. Ron Howell, CEO and President of HST Global stated, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.”
One of EBITDA Capital’s tasks was to develop a working relationship with the Chinese Government and Congressman Sarpalius just completed his initial trip to establish the working relationship. After his trip he reported, “Every community in China has a cancer center and the Chinese government is committed to treatment of the disease.” Congressman Sarpalius has commitments from both the government and privately sanctioned investors to commence negotiations with HSTC for both direct investment into HSTC and a license for the treatment protocols. The company expects to host the Chinese delegation within the next thirty days. Ms. Jenny Guo, of Advantage Associates, will host the delegation to be received by Ron Howell in the United States.
About HST Global, Inc.
HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.
Contact:
HST Global, Inc
Investor Relations
Wesley Tate (757)-766-6100
ir@hstglobal.com
www.hstglobal.com
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
About StockProfit.com
StockProfit.com specializes in using technical analysis to identify stocks in particularly powerful up-trends, then pinpoint the optimal time to enter these stocks. Additionally, StockProfit.com is an online resource for aggressive risk-tolerant market participants who wish to learn about select growth companies and other ideas that could offer potentially superior investment returns. Research and due diligence tools such as Company Profiles, Technical Trading Alerts, detailed investment opinion reports, and regular email updates of Featured Companies are some of the services we provide to our readership. For more information, visit http://www.stockprofit.com
Disclaimer: Copyright© 2008 StockProfit™. All rights reserved. StockProfit™ is an independent electronic publication providing information on select public companies. StockProfit™ is not a registered investment advisor or broker-dealer. There is a risk of loss in all of trading. Past performance is no indication, nor guarantee of future results. The information contained herein is believed to be accurate. This update is provided as an information service only, and the statements and opinions in this update should not be construed as an offer or solicitation to buy or sell any security. In no event shall StockProfit™ and/or its publisher, Stock Services LLC or any of its employees or affiliates, be liable for any direct, incidental, consequential, indirect or punitive damages whatsoever arising out of the use of the Information, or for any errors or omissions in the content thereof, including, but not limited to, from any investment loss, damage or expense incurred by any investor resulting from the Information, or from the purchase or sale of any profiled company or any company which we make commentary. We recommend using good-'till-cancelled stop orders to minimize losses in the event of an adverse price movement. We have been compensated $ 2,500 and expect to receive 27,500 Rule 144 shares by the Company for Profile Coverage. For further information, please visit http://www.stockprofit.com/disclaimer/
CONTACT: Alan Klitenic, Stock Services LLC, TEL: 818 334 4469 EMAIL: amk@stockprofit.com
###
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com
P.A. Relations
Alan Klitenic
818-334-4469
amk@stockprofit.com 
Source: EmailWire.com
(EMAILWIRE.COM, August 28, 2008 ) HAMPTON, VA -- HST Global, Inc. (OTCBB: HSTC) is pleased to announce that it has, through its contracted partner EBITDA Capital LLC of Newport Beach California and its group of associates, commenced negotiations with the Chinese Government for both direct investment and a license for their treatment protocols.
Mr. Ron Howell, CEO and President of HST Global stated, “Through the use of the EBITDA Capital resources we at HST Global can focus on the issue of bringing awareness of our treatment and solution for late stage cancer treatment to the Chinese community. We want to insure that our treatment is being given every opportunity to be recognized as the medical solution alternative of choice throughout the world.”
One of EBITDA Capital’s tasks was to develop a working relationship with the Chinese Government and Congressman Sarpalius just completed his initial trip to establish the working relationship. After his trip he reported, “Every community in China has a cancer center and the Chinese government is committed to treatment of the disease.” Congressman Sarpalius has commitments from both the government and privately sanctioned investors to commence negotiations with HSTC for both direct investment into HSTC and a license for the treatment protocols. The company expects to host the Chinese delegation within the next thirty days. Ms. Jenny Guo, of Advantage Associates, will host the delegation to be received by Ron Howell in the United States.
About HST Global, Inc.
HST Global, Inc. is a development stage biotechnology company that acquires and develops innovative products for the treatment of cancer. We focus on in-licensing drug candidates that are undergoing or have already completed initial clinical testing for the treatment of cancer, and then developing those drug candidates for commercial use.
Contact:
HST Global, Inc
Investor Relations
Wesley Tate (757)-766-6100
ir@hstglobal.com
www.hstglobal.com
HST Global, Inc. wishes to inform readers that forward-looking statements in this release are made pursuant to the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995. Readers are cautioned that such forward looking statements involve risks and uncertainties including, without limitation, unforeseen changes in the course of research and development activities and in clinical trials by others; possible acquisitions of other technologies, assets or businesses; possible actions by customers, suppliers, competitors, regulatory authorities; and other risks detailed from time to time in the Company's periodic reports filed with the Securities and Exchange Commission.
About StockProfit.com
StockProfit.com specializes in using technical analysis to identify stocks in particularly powerful up-trends, then pinpoint the optimal time to enter these stocks. Additionally, StockProfit.com is an online resource for aggressive risk-tolerant market participants who wish to learn about select growth companies and other ideas that could offer potentially superior investment returns. Research and due diligence tools such as Company Profiles, Technical Trading Alerts, detailed investment opinion reports, and regular email updates of Featured Companies are some of the services we provide to our readership. For more information, visit http://www.stockprofit.com
Disclaimer: Copyright© 2008 StockProfit™. All rights reserved. StockProfit™ is an independent electronic publication providing information on select public companies. StockProfit™ is not a registered investment advisor or broker-dealer. There is a risk of loss in all of trading. Past performance is no indication, nor guarantee of future results. The information contained herein is believed to be accurate. This update is provided as an information service only, and the statements and opinions in this update should not be construed as an offer or solicitation to buy or sell any security. In no event shall StockProfit™ and/or its publisher, Stock Services LLC or any of its employees or affiliates, be liable for any direct, incidental, consequential, indirect or punitive damages whatsoever arising out of the use of the Information, or for any errors or omissions in the content thereof, including, but not limited to, from any investment loss, damage or expense incurred by any investor resulting from the Information, or from the purchase or sale of any profiled company or any company which we make commentary. We recommend using good-'till-cancelled stop orders to minimize losses in the event of an adverse price movement. We have been compensated $ 2,500 and expect to receive 27,500 Rule 144 shares by the Company for Profile Coverage. For further information, please visit http://www.stockprofit.com/disclaimer/
CONTACT: Alan Klitenic, Stock Services LLC, TEL: 818 334 4469 EMAIL: amk@stockprofit.com
###
This press release was issued through GroupWeb EmailWire.Com. For more information on unlimited press release distribution service, go to http://www.emailwire.com
P.A. Relations
Alan Klitenic
818-334-4469
amk@stockprofit.com
Source: EmailWire.com
|
|
|
|
